Can a bile acid blocker ease severe itching in a rare liver disease?
NCT ID NCT04483531
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This expanded access program offers the experimental drug odevixibat to people with progressive familial intrahepatic cholestasis (PFIC) who have severe itching and high bile acid levels but cannot join the main clinical trial. The drug works by blocking a bile acid transporter in the gut, which may lower bile acids and reduce itching. The program aims to provide treatment access for patients of any age who meet specific criteria.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called odevixibat (A4250) that blocks a bile acid transporter in the gut
- What this could lead to
- If it works, this could provide a treatment option for people with PFIC who have severe itching and high bile acid levels.
- What could go wrong
- This is an expanded access program, not a controlled trial, so results may be less clear. The drug may not relieve symptoms or could cause side effects like diarrhea or liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Albireo Pharma Inc.
Boston, Massachusetts, 02109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug shows promise for babies with rare liver disorders
- New registry tracks Real-World use of PFIC drug odevixibat
- Baby jaundice may leave lasting marks on teeth, new study investigates
- New drug livmarli tracked for Long-Term safety in kids with rare liver disorders
- Gene hunt for mysterious adult liver disease
- Liver drug maralixibat tested for Long-Term safety in rare disease patients